100 Bayer Road
It all starts with a friendship between two men, plenty of natural curiosity and two kitchen stoves. Businessman Friedrich Bayer and dyer Johann Friedrich Weskott use these to conduct experiments and eventually discover how to make the dye fuchsine.
On August 1, 1863, they found the "Friedr. Bayer et. comp." company in Wuppertal-Barmen, a 19th century startup with tremendous potential.
Bayer is a Life Science company with a more than 150-year history and core competencies in the areas of health care and agriculture. With our innovative products, we are contributing to finding solutions to some of the major challenges of our time.
Our goal is to create value for our customers, stockholders and employees, while also strengthening the company’s earning power. We are committed to operating sustainably and addressing our social and ethical responsibilities. Employees with a passion for innovation enjoy excellent development opportunities at Bayer.
All this goes to make up our purpose: Science for a better life.
Passion to innovate | Power to change
509 articles with Bayer
At the same time that Bayer AG announced it was planning to eliminate about 4,500 jobs in Germany, it is adding about 150 jobs over the next three years in Massachusetts.
Bayer Only Life Science Company Named as a Most Reputable Company in Biggest-Ever Corporate Reputation Study in U.S.
Company Snags 68th Spot in Reputation Institute's 12th-annual US RepTrak® 100
Company Earns 100 percent on Human Rights Campaign Foundation's 17th Annual Scorecard on LGBTQ Workplace Equality
Leaps by Bayer and Khloris join forces to develop induced pluripotent stem cells (iPSCs) as breakthrough anti-cancer vaccines
Leaps by Bayer, the investment arm of the global life sciences company Bayer, and Khloris Biosciences, a biotechnology company, announced today that they have joined forces to develop novel, first-in-class anti-cancer vaccines based on human induced pluripotent stem cells (iPSCs).
The Climate Corporation and Lindsay Corporation Partner to Deliver Data-Driven Irrigation Management Insights for Farmers
The Climate Corporation announced a platform agreement that will establish two-way data connectivity between The Climate Corporation's Climate FieldView™ digital agriculture platform and Lindsay's FieldNET platform.
Bayer released the following statement in reaction to the phase two verdict in favor of the plaintiff in the case of Hardeman v Monsanto, a trial conducted in the federal glyphosate multi-district litigation before Judge Vince Chhabria in the Northern District of California.
Includes oral presentation on data from ongoing Phase I study with BAY 2731954 (formerly LOXO-195), a tropomyosin receptor kinase (TRK) inhibitor that is currently being investigated in patients who have progressed or were intolerant to prior TRK inhibitors
St. Louis, Missouri is one of the fastest-growing and top-ranked emerging life sciences markets in the U.S., ranking sixth in a recent CBRE Research report.
Both Bayer and J&J claim the lawsuits are without merit but believe that the $775 million settlement will allow the companies to move on from costly litigation.
Bayer released the following statement in reaction to a phase one verdict in favor of the plaintiff in the case of Hardeman v Monsanto, a trial conducted in the federal glyphosate multi-district litigation before Judge Vince Chhabria in the Northern District of California.
No one should start, stop or modify an aspirin regimen without first speaking with their healthcare provider.
Bayer's Phase III Clinical Trial Of Nifurtimox In Pediatric Patients With Chagas Disease Meets Primary Endpoint
Bayer presented results today from the CHICO part (CHagas disease In Children treated with NifurtimOx) of the phase III clinical study of investigational nifurtimox in pediatric patients with Chagas disease at the "XV Taller sobre la enfermedad de Chagas" conference in Barcelona, Spain.
The Climate Corporation and NAU Country Insurance Company Partner to Enable Seamless Crop Insurance Reporting for U.S. Farmers
The Climate Corporation, a subsidiary of Bayer, announced a platform agreement between the company's industry-leading Climate FieldView™ digital agriculture platform and NAU Country Insurance Company, a QBE Insurance Company.
Evotec Receives Milestone Payment For Start Of Second Phase Ii Trial In Its Multi-target Alliance With Bayer
Evotec AG announced that another promising small molecule from its multi-target alliance with Bayer has advanced into Phase II clinical development for the treatment of persistent chronic cough.
Could a product in a weed killer contribute to the development of a cancer? That is the question a jury will answer as Bayer faces accusations that glyphosate, the active ingredient in its top=selling weed killer Roundup, caused cancer in some individuals who have used the product.
BioSpace gathered together a roundup of global biopharma news from the past week. Bayer and Orion Corporation, Themis Bioscience, Axonics Modulation Technologies, and more are mentioned in this edition.
Bayer completes rolling submission of New Drug Application to U.S. Food and Drug Administration for investigational drug darolutamide for the treatment of non-metastatic castration-resistant prostate cancer (nmCRPC)
Bayer announced the completion of the rolling submission of a New Drug Application to the U.S. Food and Drug Administration for the investigational drug darolutamide.
"Wall Smashing" Ceremony Initiates Construction Of Bayer Funded Geospatial Innovation And Resource Center at T-REX Business Incubator
"Geosaurus, Powered by Bayer" Will Support Start-Ups and Workforce Programs Focused on Geospatial Technology
If you’re in the pharma or biotech industry and are looking for work, multiple companies have announced expansions of their employee pool over the past few days. BioSpace rounds up a few of the announcements.
As the American Society of Clinical Oncology 2019 Genitourinary Cancers Symposium (ASCO GU) rolls on, companies are showcasing more data in presentations. BioSpace takes a look at some of the latest.